The theme of this year’s International Society for Medical Publishing Professionals (ISMPP) 2022 Annual Meeting was “Future Ready Medical Communications.”
From training artificial intelligence “dragons” to guidance on the use of social media, it is clear from the summaries in this pamphlet that our field is planning for the future of publishing technology. Even more importantly, discussions on diversity in our workplace and the patient’s role in the publishing process ensure that our future continues to grow in a way that includes all. We also witnessed the evolving landscape of publishing guidelines through the first update to Good Publication Practice (GPP) since 2015 and the showcase of an authorship algorithm designed to help interpret the International Committee of Journal Medical Editors (ICJME) recommendations.
The meeting also reflects the first gathering of medical publication professionals after two years of COVID-19. It should come as no surprise, then, that several presentations revolved around the new landscape of congresses and the decentralization of clinical trials. The meeting also outlined experiences in new multimedia ventures such as podcasts and publishing ecosystems.
This may not have been the first attendance for many of us employed at Ashfield MedComms, ApotheCom, and Nucleus Global; however, it was the first time that we attended together as soon-to-be members of Inizio Medical. Like the “Future Ready” theme of this year’s meeting, Inizio combines the power of these three companies to define the future of medical in drug development and commercialization.
Download the ISMPP AM 2022 Report below.
Jump to a slide with the slide dots.
Inizio Engage conducted an independent market research study to explore the future of engagement with HCPs.
Read moreIn today’s rapidly evolving healthcare landscape, innovative partnerships are crucial to overcoming key brand challenges and driving measurable impact
Read moreHarness the collective expertise of our biotech experts to maximize the value of your asset across every step of your journey to commercialization.
Read more